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Cardiotoxicity is a troubling long-term side effect of chemotherapy cancer treatment, affecting therapy and
quality of life. Exercise is beneficial in heart failure patients and in cancer survivors without heart failure, but has
not been tested in cancer survivors with treatment-induced heart failure. We present case studies for two sur-
vivors: a 56-year-old female Hodgkin’s lymphoma survivor (Patient 1) and a 46-year-old male leukemia survivor
(Patient 2). We conducted a 16-week exercise program with the goal of 30 minutes of exercise performed 
3 times per week at a minimum intensity of 50%heart rate reserve or “12” rating of perceived exertion (RPE).
Patient 1 improved from 11.5 minutes of exercise split over two bouts at an RPE of 13 to a 30-minute bout at
an RPE of 15. Patient 2 improved from 11 minutes of exercise split over two bouts at an RPE of 12 to an 
18-minute bout at an RPE of 12. Both improved in V
.
O2peak (Patient 1: 13.9 to 14.3 mLO2·kg−1·min−1; Patient 2:
12.5 to 18.7 mLO2·kg−1·min−1). Ejection fraction increased for Patient 2 (25–30% to 35–40%) but not for
Patient 1 (35–40%). Quality of life as assessed by the SF-36 Physical Component Scale improved from 17.79
to 25.31 for Patient 1, and the Mental Component Scale improved from 43.84 to 56.65 for Patient 1 and from
34.79 to 44.45 for Patient 2. Properly designed exercise interventions can improve physical functioning and
quality of life for this growing group of survivors. [J Exerc Sci Fit • Vol 9 • No 1 • 65–73 • 2011]
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Introduction
The nation’s 35-year war on cancer has resulted in
increased survival for an increasing number of those
diagnosed with cancer. Today, there are at least an
estimated 12 million U.S. cancer survivors, a number
projected to continue to escalate dramatically
(National Cancer Institute 2009). However, the inten-
sive, multimodality treatments that have improved
cancer survival have come at a cost, frequently result-
ing in lasting or late-term side-effects on physical func-
tioning and quality of life (QOL). Cardiotoxicity is one
of the more troubling late-term effects for cancer sur-
vivors who have undergone chemotherapy treatment.
Many of the chemotherapy agents historically and cur-
rently used to treat cancer have toxic effects on the
heart, including arrhythmias, heart failure (HF), and
hypertension (Carver et al. 2007; Yeh et al. 2004). Left
ventricular (LV) dysfunction and HF may become evi-
dent years after cancer therapy and frequently is pro-
gressive and difficult to reverse unless identified early
(Jensen et al. 2002). Antiangiogenic agents are being
used extensively in cancer therapy and for cancer
treatment, and it is likely that these treatments will
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also have long-term implications for survivors’ cardiac
health. Studies to date document an association
between drugs such as bevacizumab (Avastin), suni-
tinib (Sutent) and sorafenib (Nexavar) with cardiovas-
cular toxicity (Khakoo et al. 2008; Force et al. 2007).
The use of exercise to ameliorate chemotherapy-
induced HF has not been studied. However, exercise
has been studied and confirmed to be beneficial in
patients with HF not related to cancer therapy (van Tol
et al. 2006; Lee et al. 1979). Cardiac rehabilitation pro-
grams involving exercise training and other lifestyle
changes are recognized by the American Heart Associ-
ation (AHA) and the American College of Cardiology
(ACC) as useful and effective in the treatment of patients
with HF and are included in the 2009 Focused Update:
Guidelines for the Diagnosis and Management of Chronic
Heart Failure in the Adult published by the ACC Founda-
tion and the AHA (Jessup et al. 2009).
Although no studies have reported the effects of exer-
cise specifically for cancer survivors with chemotherapy-
related HF, a growing body of research demonstrates the
benefits of exercise for individuals facing cancer (Hughes
et al. 2008; Daley et al. 2007; Schmitz et al. 2005;
Courneya 2003; Fairey et al. 2002). Exercise may reduce
the risk of cancer recurrence (Meyerhardt et al. 2006b;
Holmes et al. 2005), second primary cancers, and other
chronic diseases (Devogelaer & de Deuxchaisnes 1993;
Helmrich et al. 1991), and may increase survival
(Meyerhardt et al. 2006a; Holmes et al. 2005). Other
benefits include increased muscle strength (Courneya
et al. 2007; Ahmed et al. 2006), improved physical func-
tioning (Segal et al. 2001; Mock et al. 1997), controlled
body weight (Segal et al. 2001), improved endurance
(Basen-Engquist et al. 2006), and reduced fatigue (Mock
et al. 1997). Exercise can improve specific symptoms
that interfere with daily life. For example, breast cancer
patients exercising during treatment reported less nau-
sea (MacVicar & Winningham 1986) and better sleep
(Mock et al. 1997), and those exercising post-treatment
showed improved cardiopulmonary fitness (Courneya
et al. 2003), decreased pain (Basen-Engquist et al. 2006),
and lower blood pressure (Pinto et al. 2003). The re-
search regarding exercise and improvement in cancer
survivorship also has a number of limitations. First, there
are no studies specifically addressing the benefits for
cancer survivors with treatment-related HF. In fact, can-
cer survivors with HF usually are not “eligible” for these
studies due to exclusion criteria. Second, much of the
research has focused specifically on breast cancer sur-
vivors. While research indicates that exercise training
benefits HF patients, to our knowledge, there is no
published research on the use of exercise to improve
or prevent HF in patients treated for cancer.
Our long-term goal is to conduct a randomized con-
trol trial of an exercise intervention for cancer survivors
who have developed HF as a result of chemotherapy.
Here, we present the findings from our first two partici-
pants that provide compelling evidence that properly
designed exercise interventions can greatly benefit
this emerging population of cancer survivors.
Methods
Our primary interest in conducting the pilot study was
three-fold: (1) assess the feasibility of conducting the
trial; (2) validate the methodology prior to conducting an
efficacy trial; and (3) assess the effectiveness of an indi-
vidualized 16-week exercise intervention on our out-
come variables (cardiorespiratory fitness, HF symptoms,
HF progression, and QOL). Our two pilot participants
were the first two cancer survivors to complete the study.
University of Texas M.D. Anderson Cancer Center
(MDACC) institutional review board approval was
obtained prior to recruiting participants. To participate
in the pilot study, participants must have been diag-
nosed with New York Heart Association HF functional
classification of II or III within the past 6 months and
have had previous chemotherapy that contributed to
the development of HF.
Cardiology physical assessment
Participants underwent an initial cardiology-based phys-
ical assessment including medical history, a physical
examination, an echocardiogram, electrocardiogram
(ECG), cardiac biomarkers (BNP and troponin), and
were determined to be stable for exercise. Informed
consent was obtained and the patient was scheduled
for a baseline fitness assessment in the Behavioral
Research and Treatment Center (BRTC) at MDACC.
Fitness assessment
At the BRTC, the Seven-Day Physical Activity Recall
Questionnaire (7-DPARQ) (Rauh et al. 1992) was con-
ducted in an interview format to estimate the partici-
pants’ usual level of activity prior to beginning the
program. After the interview, participants completed a
resting ECG and measurements of resting heart rate and
blood pressure. They then performed a symptom-limited
maximal exercise test. Patient 1 completed the exercise
test on a cycle ergometer and Patient 2 completed the
exercise test on a motorized treadmill (he exceeded
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the recommended weight limit for the cycle ergometer).
At the start of the test, research staff explained the test
and use of the Borg rating of perceived exertion (RPE)
scale (Borg 1998). The metabolic cart used was the Parvo
TrueOne cart (ParvoMedics, Sandy, UT, USA), which
interfaced with the Quinton 5000 (Quinton Cardiology
Systems Inc., Bothell, WA, USA) ECG recording machine
and a Lode Corival cycle ergometer (in the case of
Patient 2, a Tracmaster treadmill). The specific proto-
cols detailed below were pre-programmed into the
metabolic cart which automatically controlled the resis-
tance for the cycle and the treadmill speed and eleva-
tion. The same individual protocol used for the baseline
fitness assessment was repeated for the follow-up
assessment.
For Patient 1, the protocol started by setting resis-
tance at 10 W for a 5-minute warm-up period. Patient 1
was instructed to pedal at a target cadence of 60 RPM
throughout the exercise test. After the warm-up period,
1 W of resistance was added every 6 seconds until she
reached maximal effort. The exercise test termination
point was pre-defined by any one of five criteria: (1)
patient volitionally stopping; (2) abnormal hemody-
namic responses to workload; (3) inability to maintain
cadence on the cycle; (4) unexpected arrhythmias
detected on ECG; or (5) loss of any monitoring signal.
Patient 1 reached the point where she could no longer
maintain cadence on the cycle at which point load was
reduced to 10 W for a minimum of 5 minutes until
blood pressure and heart rate returned to approxi-
mately pre-exercise stage levels.
For Patient 2, the protocol started with a 3-minute
warm-up phase at a speed of 1.5 mph and 0% grade.
After warm-up completion, the treadmill speed increased
by 0.5 mph every 2 minutes with the elevation grade
remaining at 0% until he could no longer maintain
treadmill speed. The exercise test termination point
was pre-defined by any one of five criteria: (1) patient 
volitionally stopping; (2) abnormal hemodynamic
responses to workload; (3) inability to maintain cadence
on the cycle; (4) unexpected arrhythmias detected on
ECG; or (5) loss of any monitoring signal. Patient 2
reached the point where he could no longer maintain
treadmill pace. At termination of the exercise stage, the
treadmill speed was reduced to 1.0 mph and 0% grade
for a minimum of 3 minutes until blood pressure and
heart rate returned to approximate pre-exercise levels.
Participants rated perceived exertion every 2 minutes
throughout the test using the Borg “6–20” RPE scale
(Borg 1998). Blood pressure was taken with an auto-
mated cuff every 2 minutes. ECG was continuously
monitored throughout the test and recorded. Peak oxy-
gen uptake value (V
.
O2peak, mLO2·kg−1·min−1) was set
as the mean oxygen uptake over the last 30 seconds of





was also noted prior to cool-down. Ventilatory threshold
was assessed with Parvo TrueOne software (ParvoMedics)
using the respiratory exchange gas data and being
defined using the “V-slope” method or at the point of
abrupt nonlinear increase in the slope of minute ventila-
tion (V
.
E) during increased workload (Beaver et al. 1986).
Measures
QOL
Two measures were used to assess QOL, the Medical
Outcomes Short Form-36 (SF-36) and the M.D.
Anderson Symptom Inventory-Heart Failure (MDASI-
HF). The SF-36 is a 36-item generic measure for health
concepts (Ware et al. 2000). A typical example ques-
tion from the SF-36 is: “During the past week, how
much of the time have you had to cut down on the
amount of time you spent on work or other daily activ-
ities as a result of your physical health?” The response
choices are: 1—All of the time; 2—Most of the time;
3—Some of the time; 4—A lot of the time; and 5—
None of the time. The 36 individual items load on
eight subscales, which can be combined into two inde-
pendent summary measures, Physical Component
Scale (PCS) and Mental Component Scale (MCS).
Reliability estimates for the summary scores exceed
0.90 (Ware et al. 2000). Higher scores on the subscales
and summary scores indicate better QOL.
HF symptoms were measured with the MDASI-HF.
This 27-item questionnaire measures symptoms com-
monly associated with HF for cancer patients and
their impact on daily functioning (Fadol et al. 2008). It
has high internal consistency reliability for the general
symptom scale (Cronbach’s alpha = 0.89), HF symp-
toms (Cronbach’s alpha = 0.83) and the functioning
interference items (Cronbach’s alpha = 0.92). The scales
correlate with New York Heart Association classification
and the Eastern Cooperative Oncology Group perfor-
mance status, and differentiate HF patients with high
and normal BNP, a cardiac marker for volume over-
load (Fadol et al. 2006).
7-DPARQ
Physical activity was also assessed based on the 
7-DPARQ (Sallis 1997). The 7-DPARQ is an interviewer-
administered self-report recall instrument assessing
physical activity during the past 7 days. Information
on moderate, hard, and very hard activities is gathered
J Exerc Sci Fit • Vol 9 • No 1 • 65–73 • 2011 67
D.C. Hughes et al.
during the interview and time spent in light activities
is imputed from the information. The 7-DPARQ also
asks about time spent in activity to increase strength
and flexibility. The 7-DPARQ has been widely used to
obtain self-report activity with acceptable validity and
reliability (Sallis 1997).
Exercise sessions
The objective in the design of the exercise prescription
was to increase exercise duration, then intensity, with
the ultimate goal to increase exercise tolerance to at
least 30 minutes of continuous exercise at an intensity
level of at least 50% heart rate reserve. The heart rate
reserve method along with RPE was used to determine
the intensity of the exercise and to adjust the exercise
prescription as needed. We used the RPE method for
adjusting intensity during the supervised exercise ses-
sions as resting heart rate would vary greatly in our
participants with each visit. The participants came to
the MDACC BRTC three times a week. A recumbent
cycle (PRECOR model C846i; PRECOR, Woodinville,
WA, USA) was used during the supervised sessions.
Supervised exercise sessions
Participants’ weight, resting heart rate and blood pres-
sure were recorded at each supervised exercise session
upon arrival. During the initial 4 weeks, ECG was mon-
itored continuously during exercise. Though resting
heart rate was noted and heart rate reserve method
intensity calculated, the intensity was prescribed and
monitored with the Borg “6–20” RPE scale (Borg
1998). (RPE was used as the day-to-day resting heart
rate was extremely variable for both participants.)
During their initial sessions, both Patient 1 and Patient
2 were instructed to cycle at an intensity level of an
RPE of 12 on the scale (i.e., between “fairly light” and
“somewhat hard”). The intent was to increase exercise
duration and then increase intensity incrementally as
exercise tolerance improved.
Home-based exercise sessions
After at least 8 weeks of supervised exercise sessions
and after clearance from the cardiologist to exercise at
home, both participants were encouraged to continue
exercise activities at home. Both were given home logs
to complete to record the minutes of exercise and the
intensity of exercise (RPE). Logs were reviewed each
week during the supervised sessions and any program
adjustments were made. Initially, the at-home sessions
were prescribed with less duration and less intensity than
the supervised sessions but then gradually increased.
Results
Two participants completed our intervention: Patient 1,
a 56-year-old female survivor of Hodgkin’s lymphoma;
and Patient 2, a 46-year-old male survivor of leukemia.
Review of medical records indicated that prior to can-
cer treatment, both had had normal cardiac function.
Both participants, though quite different in physical
characteristics and compliance to suggested at-home
exercise sessions, made significant improvements in
exercise tolerance and cardiorespiratory capacity as a
result of participating in the program (Tables 1 and 2).
Both participants had no evidence of disease (cancer),
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Table 1. Exercise intervention results for pilot participants
Patient 1 Patient 2
Pre Post Pre Post
V
.
O2peak (mLO2·kg−1·min−1) 13.87 14.30 12.5 18.7
Ventilatory threshold (% of peak) 80 95 78 66
Respiratory exchange ratio 0.998 1.054 1.123 1.132
Maximum exercise heart rate 116 123 134 167
Body mass index [kg·(m2)−1] 20.2 20.2 57.6 57.9
Ejection fraction (%) 35–40 35–40 25–30 35–40
BNP (pg·mL−1) 124 56 46 115
Troponin (ng·mL−1) 0.04 < 0.03 N/A* < 0.03
SF-36 PCS score 17.79 25.31 21.03 21.05
SF-36 MCS score 43.84 56.65 34.79 44.45
MDASI-HF symptoms 3.3 2.2 5 3.3
7-day recall MET-hours·week−1 17 20 1 9
*Missing.
and had normal blood count and hemoglobin levels
before beginning the exercise program.
Patient 1
Our initial participant developed HF as a result of
anthracycline-based chemotherapy received 13 years
previously. The baseline echocardiogram assessment
indicated an ejection fraction of 35–40%, BNP was
124 pg·mL−1 and troponin level was 0.04 ng·mL−1.
She weighed 57.4 kg, with a BMI of 20.2 kg·(m2)−1.
The exercise test indicated cardiorespiratory capacity
(V
.
O2peak) of 13.87 mLO2·kg−1·min−1, well below the
10th percentile as reported by American College of
Sports Medicine (ACSM) normative standards (ACSM
2009). She attained an RER of 0.998 while reaching a
maximum of 57 W of resistance prior to not being
able to maintain cadence. Ventilatory threshold was
80% of peak (11.10 mLO2·kg−1·min−1) as estimated
using the “V-slope” method (Beaver et al. 1986). QOL
scores as assessed by the SF-36 were well below aver-
age as reported by PCS score of 17.79 ( > 3 standard
deviations below the U.S. population norm of 50) and
an MCS score of 43.84 (approximately 0.6 standard
deviation below the norm of 50). She self-reported 17
MET-hours·week−1 of moderate or higher activity in the
week prior to the baseline as indicated by the 7-DPARQ.
During the first 8 weeks of the intervention, Patient 1
attended 19 supervised exercise sessions. She increased
her exercise tolerance from 11 minutes of exercise
over two 5.5-minute bouts (with a 3-minute rest in
between the bouts) to one continuous bout of exercise
for 27 minutes. After her 8-week physical (physicals
were conducted approximately every 4 weeks), she
was cleared to begin home-based exercise sessions.
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Table 2. Cardiac rehabilitation exercise intervention data
Patient 1 Patient 2
First three sessions
Minutes exercising per session 11.5 11
Longest bout 7.0 5.8
RPE 13 12
Last three sessions
Minutes exercising per session 30 18
Longest bout 30 18
RPE 15 12
Number of exercise sessions
Supervised 35 15
Home: unsupervised 20 N/A*
*Patient 2 did not log his home-based exercise bouts.
For the next 10 weeks (2 weeks were lost to hurri-
cane Ike), she completed 36 bouts of exercise, each of
approximately 30 minutes’ duration. Of the 36 bouts,
20 were completed at home. During her supervised
sessions, exercise intensity using the Borg scale (Borg
1998) was increased slightly (from an RPE of 12–14 to
an RPE of 14–15) while maintaining the 30-minute
duration. She was encouraged to increase her exercise
intensity as well during the unsupervised home-based
sessions. (RPE was chosen due to the day-to-day vari-
ability of resting heart rate). Participant 1 then met our
target goal of at least 30-minute bouts of exercise at a
moderate level of intensity. In total, Patient 1 com-
pleted 1,155 minutes of exercise at targeted intensity
levels (excluding warm-up and cool-down) over 56 ses-
sions, of which 36 (65%) were supervised at the BRTC.
At the end of the 16-week period, the cardiac, QOL
and exercise assessments were repeated. Although
estimated ejection fraction remained the same
(35–40%), BNP and troponin blood levels improved from
abnormally high levels to within normal limits (124 to
56 pg·mL−1 and 0.04 to < 0.03 ng·mL−1, respectively).
V
.
O2peak improved from 13.87 to 14.30 mLO2·kg−1·
min−1 with ventilatory threshold improving from 80%
to 95% of V
.
O2peak. Maximum resistance increased to
67 W with an RER of 1.054. In assessing QOL with the
SF-36, PCS improved from 17.79 to 25.31 and MCS
improved from 43.84 to 56.65. Average HF symptoms
decreased as assessed by the MDASI-HF from 3.3 to
2.2 (0 = “no symptoms”, 10 = “as bad as can be imag-
ined”). She self-reported increased levels of moderate
or higher activity in the week prior to the post assess-
ment as indicated by the 7-DPARQ of 20 MET-hours·
week−1, an increase from the 17 MET-hours·week−1 at
baseline.
Patient 2
Our second participant was treated with anthracycline-
based chemotherapy for leukemia 5 years previously.
In 2007, he presented with ventricular tachycardia sec-
ondary to electrolyte imbalance. Subsequent echocar-
diogram showed LV dysfunction and he experienced
significant HF symptoms.
The baseline echocardiogram assessment indicated
an ejection fraction of 25–30%, BNP was 46 pg·mL−1
and troponin was not assessed. He weighed 175.4 kg
with a BMI of 57.6 kg·(m2)−1. The exercise test in-
dicated cardiorespiratory capacity (V
.
O2peak) of 12.5
mLO2·kg−1·min−1, below the 10th percentile as re-
ported by ACSM normative standards (ACSM 2009).
He attained an RER of 1.123 while reaching a treadmill
speed of 2.5 mph prior to not being able to maintain
walking speed. Ventilatory threshold was 78% of peak
(9.75 mLO2·kg−1·min−1) as estimated using the 
“V-slope” method (Beaver et al. 1986). QOL scores as
assessed by the SF-36 were well below average as
reported by a PCS score of 21.03 (almost 3 standard
deviations below the U.S. population norm of 50) and
a MCS of 43.79 (well below the norm of 50). He self-
reported only 1 MET-hours·week−1 of moderate or
higher activity in the week prior to the baseline as indi-
cated by the 7-DPARQ.
During the intervention, Patient 2 attended 15 exer-
cise sessions, all supervised. In contrast to Patient 1,
Patient 2 inconsistently reported any home activity
(i.e., he did not complete any logs). Moreover, Patient 2
was less consistent in attending the supervised sessions.
However, he did increase his exercise tolerance from 
9 minutes of exercise over two 4.5-minute bouts with
a 3-minute rest interval to one continuous bout of 
18 minutes. During his supervised sessions, exercise
intensity using the Borg scale (Borg 1998) was increased
slightly from an RPE of 12 to an RPE of 13. Similar to
Patient 1, the focus first was on increasing exercise dura-
tion, then intensity. However, Patient 2 did not meet our
target goal of 30 minutes of exercise. Because Patient
2 did not reach the goal of 30 minutes of continuous
exercise, we maintained a lower intensity. Like Patient 1,
Patient 2 was also encouraged to exercise at home and
to log any activity. Patient 2 reported doing activities
recommended but did not consistently document those
activities. Therefore, it was difficult to determine how
many total minutes of exercise Patient 2 achieved at
home. He completed 15 supervised sessions with a total
of 198 minutes of exercise at targeted intensity levels
(excluding warm-up and cool-down).
At the end of the 16-week period, the cardiac, QOL
and exercise assessments were repeated. Ejection frac-
tion improved from an estimated 25–30% to 35–40%.
(Troponin assessment was missed at baseline.) BNP
changed from 46 to 115 pg·mL−1 and troponin blood
level was < 0.03 ng·mL−1. V
.
O2peak improved from 12.5
to 18.7 mLO2·kg−1·min−1 with ventilatory threshold
changing from 78% to 66% of V
.
O2peak. He attained an
RER of 1.132 while reaching a treadmill speed of 3.0
mph prior to not being able to maintain walking speed.
Unlike Patient 1, QOL assessed by the SF-36 PCS stayed
the same (21.05 vs. 21.03); however, similar to Patient 1,
MCS improved from 34.79 to 44.45. HF symptoms de-
creased from 5 to 3.3. He self-reported 9 MET-hours·
week−1 of moderate or higher activity in the week prior
to the post assessment as indicated by the 7-DPARQ,
an increase from the 1 MET-hours·week−1 reported at
baseline.
Discussion
Though our participants presented with similar
chemotherapy-related HF and with very low levels of
exercise tolerance at the beginning of the study, they
were very different physically (i.e., BMI of 20.2 for
Patient 1 vs. a BMI of 57.6 for Patient 2), and different in
terms of compliance to home-logs and attendance at
supervised sessions. In addition, the disparities in self-
reported physical activity should be noted. The high
self-reported baseline activity for Patient 1 may be an
indication that tasks perceived as light for most healthy
individuals may be perceived as moderate to strenuous
for someone with low cardiorespiratory capacity. This is
also suggested for Patient 1 based on the relatively lower
RER (0.998) level at the end of the initial exercise test,
though the second exercise test RER level (1.054) was
a little more indicative of a true physiological maximum.
The cardinal message here is that despite these differ-
ences in physical stature and self-report, both Patient 1
and Patient 2 greatly benefited from the intervention,
with significant gains in exercise tolerance and QOL.
An important element to the effectiveness of the
intervention was that the intervention progressed
from highly monitored supervised exercise sessions in
a laboratory setting to independent home-based exer-
cise intervention with self-monitoring. This transition
from supervised exercise to independent exercise may
very well have increased confidence in increasing
exercise behaviors. The intervention was designed in
this way to facilitate longer-term maintenance of exer-
cise so that the gains realized during the intervention
might be maintained and perhaps improved upon.
This obviously would be of tremendous long-term ben-
efit for our participants.
Though we report on only two participants, our ini-
tial results are consistent with published findings on
exercise programs for cardiac rehabilitation in patients
with HF resulting in improved functional capacity and
QOL (Jonsdottir et al. 2006; van Tol et al. 2006; Kavanagh
et al. 2002). Some studies have shown improvement
in V
.
O2peak (Barlow et al. 1994; Coats et al. 1992) while
others have not (Jonsdottir et al. 2006; Belardinelli et al.
1999). In our two case studies, one participant, Patient
2, improved V
.
O2peak (12.5 to 18.7 mLO2·kg−1·min−1),
whereas Patient 2 stayed at approximately the same
level (13.87–14.30 mLO2·kg−1·min−1). Consistent with
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the published literature, despite the lack of consistent
results for our two participants in V
.
O2peak, BNP and
ejection fraction, both our participants benefited in in-
creased exercise tolerance and QOL. The importance
of exercise training as being useful and effective in
patients with HF is also recognized by both the AHA
and the ACC (Jessup et al. 2009). Our case studies
would suggest that appropriately designed exercise pro-
grams are also beneficial for cancer survivors with
chemotherapy-related HF.
The measured physical improvements for our two
participants are also coupled with improvements in
self-reported physical and mental wellbeing and in
self-reported HF symptoms. Although as stated there
were individual differences in detailed cardiac param-
eters between the two participants (LV ejection frac-
tion improved for Patient 2 but not for Patient 1; BNP
improved for Patient 1 but not for Patient 2; Patient 1
had large improvement in V
.
O2peak and Patient 2 a mar-
ginal improvement), the overall exercise tolerance and
QOL were clearly improved. Due to the small sample
size and the known variability of clinical testing
related to LV ejection fraction measurements and BNP
levels, there was no discernable trend in these param-
eters. A larger study may provide more convincing
serologic or structural improvement of cardiac status.
Although there have been many studies on exercise
for HF and an increasing number of studies on exercise
for cancer survivors, to our knowledge there have been
no published reports of exercise interventions specifi-
cally for cancer survivors with HF. These very favorable
results from our pilot participants are extremely
encouraging and provide strong preliminary evidence
that this is an important area for future research
toward improving physical functioning and QOL for
this special population of growing cancer survivors.
Results should be viewed in the context of several
limitations. One obvious limitation is that this report
relies on only two cases. Any generalizations about the
effectiveness of an exercise intervention need to be
made with caution. Moreover, the two pilot participants
were self-selected. The participants were highly moti-
vated to participate in the study, given their willingness
to drive into a major medical center on a frequent basis
independent of other appointments and submit to maxi-
mal exercise testing and supervised exercise sessions.
Another limitation was that the participants were not
closely monitored during their home-based exercise
and, outside of logs and self-reported data, there was no
way to accurately assess how physically active they were
outside of the supervised sessions. Moreover, there has
not been a follow-up assessment of the two pilot partici-
pants, so it is unknown how active they have stayed and
how long the benefits of the intervention have lasted.
Despite these limitations, the strengths of the study
deserve to be emphasized. The exercise prescription
was specifically designed to each individual’s fitness
level. The intervention also used RPE to prescribe and
monitor intensity. This is an important element in that
our participants would present as many HF patients
do, with differing resting heart rates and energy levels on
different days. In addition, and maybe just as impor-
tant, using RPE allowed the participants to self-monitor
their intensity levels and carry that forward to indepen-
dent, home-based exercise activities. Another strength
of the intervention was the tailored approach to proceed
from more supervised sessions (ECG monitoring, blood
pressure) to progressively less supervised sessions and
eventually a home-based exercise focus. The supervised
sessions gave participants who had extremely low ini-
tial exercise tolerance the opportunity to increase their
confidence in performing more intense, longer-duration
exercise sessions at home. Finally, to our knowledge,
this is the first exercise intervention study focused on
cancer survivors with chemotherapy-related HF. With
cancer survivorship now being a long-term condition
and with the rapidly increasing population of cancer
survivors, an increasing number of survivors can greatly
benefit from a properly designed and supervised exer-
cise intervention.
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